TUESDAY PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit

Purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive, have until Tuesday, September 22, 2026, to seek appointment as lead plaintiff of the Procept class action lawsuit. The lawsuit charges Procept and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.

The Procept class action lawsuit alleges that defendants throughout the Class Period made materially false and/or misleading statements because they failed to disclose adverse facts pertaining to Procept's business, operations, and financial condition. These included that Procept had utilized an extensive discount program to incentivize customers to place bulk orders in excess of procedure demand, which artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods. The lawsuit further alleges that this program caused customer handpiece orders to materially exceed underlying procedure demand, creating a glut of field inventory and overstocking amongst Procept's customer base, amounting to more than 10,000 excess units by the end of the Class Period.

As a result, defendants' representations regarding Procept's handpiece unit sales and the utilization of Procept's field Systems were materially overstated, and Procept was exposed to material undisclosed risks of significant operational and financial harm. Consequently, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance, which lacked a reasonably achievable factual basis.

The Procept class action lawsuit further alleges that on August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, defendant Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, defendant Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer. On this news, the price of Procept stock fell approximately 16% over a two-day trading period.